Paige was launched in early 2018 to bring technology created at Memorial Sloan Kettering to the world. MSK and Dr. Fuchs have financial interests related to Paige in the form of intellectual property rights and equity interests. The Company builds powerful, clinical-grade computational technologies to transform the diagnosis, treatment and biomarker discovery for cancer. With AI positioned to open a new future of pathology, Paige has created an AI-native digital pathology ecosystem that enables the Pathologist to achieve higher quality, faster throughput and lower cost diagnoses and treatment recommendations. Additionally, Paige accelerates new biomarker discovery, and is built to generate new insights into pathways and drug efficacy. Paige is committed to delivering the technology in a way that integrates seamlessly with hospital workflow systems and ensures safety, accuracy, and data privacy.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/18/19 | $45,000,000 | Series B |
Breyer Capital Healthcare Venture Partners Kenan Turnacioglu | undisclosed |
| 04/23/20 | undisclosed | Series B |
Goldman Sachs Merchant Banking Division | undisclosed |
| 07/14/20 | $15,000,000 | Series B |
Goldman Sachs Merchant Banking Division | undisclosed |
| 01/14/21 | $100,000,000 | Series C |
Casdin Capital Johnson & Johnson Innovation | undisclosed |
